Definium Therapeutics, Inc. (DFTX) Income Statement
DFTX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsDFTX revenue and net income
DFTX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
DFTX quarterly EPS vs estimates
Definium Therapeutics beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.55).
DFTX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $527,000 | $3.2M | — | — | — | $6,684 | $6,682 | $5,501 | — |
| Gross profit | — | −$527,000 | −$3.2M | — | — | — | −$6,684 | −$6,682 | −$5,501 | — |
| Research & development | $117.7M | $65.3M | $49.0M | $36.2M | $34.8M | $18.6M | — | — | — | — |
| Sales, general & admin | $48.6M | $38.6M | $41.7M | $30.2M | $59.1M | $14.4M | — | — | — | — |
| Total operating expenses | $166.3M | $103.4M | $90.7M | $66.3M | $93.9M | $33.0M | $461,501 | $855,262 | $1.2M | $111,252 |
| Operating income | −$166.3M | −$103.9M | −$93.9M | −$66.3M | −$93.9M | −$33.0M | −$468,180 | −$861,940 | −$1.2M | −$111,250 |
| Interest income | $11.0M | $11.6M | $5.6M | — | — | — | — | — | — | — |
| Interest expense | $5.5M | $2.3M | $920,000 | $1.5M | $359,000 | $164,000 | — | — | — | — |
| Income before taxes | −$183.8M | −$108.7M | −$95.7M | −$56.8M | −$94.2M | −$33.9M | −$1.1M | −$857,944 | −$1.2M | −$179,900 |
| Income taxes | — | — | — | — | −$1.2M | — | −$4 | −$2 | −$2 | — |
| Net income | −$183.8M | −$108.7M | −$95.7M | −$56.8M | −$93.0M | −$34.1M | −$1.1M | −$857,944 | −$1.2M | −$179,900 |
| EBITDA | −$178.3M | −$105.9M | −$92.6M | −$52.1M | −$91.2M | −$33.6M | −$1.1M | −$851,262 | −$1.5M | −$111,250 |
| EPS (diluted) | −$2.08 | −$2.02 | −$4.30 | −$1.89 | −$5.36 | −$1.31 | −$0.06 | −$2.96 | −$4.73 | −$3.40 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — | — | $527,000 | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | −$527,000 | — | — |
| Research & development | $48.7M | $41.5M | $33.5M | $31.0M | $29.8M | $23.4M | $21.8M | $17.2M | $14.6M | $11.2M | $11.5M | $13.2M |
| Sales, general & admin | $26.4M | $17.7M | $14.1M | $14.7M | $11.1M | $8.8M | $10.7M | $7.6M | $9.8M | $10.5M | $10.7M | $8.4M |
| Total operating expenses | $75.1M | $59.2M | $47.6M | $45.7M | $40.9M | $32.2M | $32.5M | $24.8M | $24.5M | $21.7M | $22.2M | $21.6M |
| Operating income | −$75.1M | −$59.2M | −$47.6M | −$45.7M | −$40.9M | −$32.2M | −$32.5M | −$24.8M | −$24.5M | −$22.2M | −$22.2M | −$21.6M |
| Interest income | $3.6M | $3.5M | $3.5M | $2.3M | $2.8M | $2.4M | $3.3M | $3.5M | — | — | — | — |
| Interest expense | $1.2M | $1.2M | $9.7M | $1.3M | $2.3M | $602,000 | $656,000 | $727,000 | $466,000 | $434,000 | — | $328,000 |
| Income before taxes | −$159.0M | −$77.1M | −$50.4M | −$67.3M | −$42.7M | −$23.3M | −$34.7M | −$13.7M | −$5.9M | −$54.4M | −$23.9M | −$17.9M |
| Net income | −$159.0M | −$77.1M | −$50.4M | −$67.3M | −$42.7M | −$23.3M | −$34.7M | −$13.7M | −$5.9M | −$54.4M | −$23.9M | −$17.9M |
| EBITDA | −$157.8M | −$75.2M | −$40.7M | −$66.0M | −$40.4M | −$22.7M | −$33.4M | −$1.1M | −$5.4M | −$53.4M | −$23.1M | −$16.8M |
| EPS (diluted) | −$1.44 | −$0.71 | −$0.45 | −$0.78 | −$0.50 | −$0.35 | −$0.41 | −$0.18 | −$0.29 | −$1.14 | −$2.44 | −$0.45 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in DFTX's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
DFTX financial results
Definium Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $183.8 million. Diluted earnings per share came to −$2.08.
See the DFTX stock overview for the latest quote and news, or the DFTX chart for price history and technical indicators.
DFTX income statement FAQ
Does Definium Therapeutics have revenue?
Definium Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Definium Therapeutics profitable?
No. Definium Therapeutics reported a net loss of $183.8 million in fiscal 2025.
How much does Definium Therapeutics spend on research and development?
Definium Therapeutics spent $117.7 million on research and development in fiscal 2025.
What are Definium Therapeutics's earnings per share?
Definium Therapeutics earned $-2.08 per diluted share in fiscal 2025, compared with $-2.02 a year earlier.
When will Definium Therapeutics report its next earnings?
Definium Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does Definium Therapeutics's fiscal year end?
Definium Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.